provided a preclinical rationale for the use of HDAC inhibitors (HDACi) to reduce HRR in HRP ovarian cancer, including CCNE1-amplified tumors, as a means to enhance PARPi activity (197). This evidence concerns the gene CCNE1 and ovarian carcinoma.